Obesity evidence dossier
Pemvidutide
A glucagon-containing profile may matter for liver fat and cardiometabolic biology, not just total body weight.
Total weight loss
15.6%
MOMENTUM · 2.4 mg weekly · week 48 · Analysis not fully specified
Placebo-adjusted
13.4%
Difference from placebo in the same study when reported.
Study context
GLP-1/glucagon dual agonist/Adults with obesity or overweight, without diabetes/391 participants across the study/48-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
MOMENTUM · 2.4 mg weekly · 48 weeks
Adults with obesity or overweight, without diabetes. 391 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Least-squares means from MMRM; the release does not specify a treatment-policy estimand.
- Average weight loss
- 15.6%
- Placebo group
- 2.2% loss
- Beyond placebo
- 13.4 percentage points (arm subtraction)
- Stopped due to adverse events
- 19.6% treatment / 6.2% placebo
Score: 70% × 64.4 total-loss points + 30% × 65.0 beyond-placebo points = 65/100, rounded. Conversion scales
Altimmune, MOMENTUM 48-week results ↗Phase 2 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
MOMENTUM: Analysis not fully specified. Least-squares means from MMRM; the release does not specify a treatment-policy estimand.
Diabetes data
Diabetes-specific data should be separated because glycemic status can change both efficacy and tolerability interpretation.
Safety
Side effects and cautions
Discontinuation read
Stopped because of adverse events: 19.6% on treatment vs 6.2% on placebo.
Common side effects
Gastrointestinal events were the main tolerability issue in the obesity program.
Main cautions
Not approved; development value depends on Phase 3 design, tolerability, and whether liver or body-composition benefits are clinically meaningful.
Upcoming catalyst
What to watch next
Later-stage obesity and MASH positioning.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06987513
Phase 2
RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Altimmune, Inc.
Non-diabetic obesity
Nov 19, 2025
NCT05295875
Phase 2
Efficacy and Safety of ALT-801 in the Treatment of Obesity
Altimmune, Inc.
Non-diabetic obesity
Nov 29, 2023
NCT04561245
Phase 1
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Altimmune, Inc.
Healthy volunteer
Jun 24, 2025
NCT05134662
Phase 1
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
Altimmune, Inc.
Type 2 diabetes / obesity
Jun 24, 2025
NCT05006885
Phase 1
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Altimmune, Inc.
Type 2 diabetes / obesity
Jul 27, 2023
NCT05292911
Phase 1
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
Altimmune, Inc.
Type 2 diabetes / obesity
Jul 27, 2023